Posters

Two years' experience with a new preloaded injector system and hydrophobic aspheric IOL material

Poster Details

First Author: M.Holzer GERMANY

Co Author(s):    S. Laupp   E. Knobloch   T. Rabsilber              

Abstract Details

Purpose:

Monofocal hydrophobic IOLs are one of the most commonly implanted lenses. Glistening formation following the implantation of such lenses can occur and might influence the quality of vision. A new glistening free hydrophobic material was developed and used for a new monofocal, blue light filtering, aspheric IOL. Additionally a new preloaded injector system for implantation of this IOL was used.

Setting:

Retrospective, single-center study. Eye Center Prof. Dr. Holzer & Prof. Dr. Rabsilber, Weinheim/Mannheim, Germany.

Methods:

Two hundred eyes following cataract surgery and routine implantation of a new monofocal hydrophobic aspheric IOL using a preloaded injector system (Clareon AutonoMe, Alcon Inc.) were included in this investigation. Injector handling, IOL power calculation accuracy and refractive outcomes as well as slit lamp findings were analyzed 1 day, 1 week, 3 and 12 up to 24 months postoperatively.

Results:

All surgeries were uneventful with normal IOL unfolding and no postoperative IOL related complications. IOL power calculation using the SRK/T formula showed a median deviation from intended refraction of 0.44 D. 81.1% of eyes achieved postoperatively a CDVA of 20/25 or better whereas the preop maximum CDVA was 20/25 in 13.5% of the eyes. Median CDVA improved from 0.25 logMAR to 0.10 logMAR postoperatively. No IOL haze or glistening was noticed postoperatively. All IOLs remained optical clear without glistening or haze formation.

Conclusions:

The new preloaded injector system was easy to handle for the OR staff and provided an excellent IOL delivery. The new IOL material revealed good functional outcomes. Slit lamp examinations showed clear IOLs with no glistening formation during the follow-up period.

Financial Disclosure:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a competing company, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a competing company